Our Venture
Catalyst
Knowledge and expertise from our Innovation Hub creates a flywheel for differentiated venture creation
Focused.
Lean.
Delivery.
Opportunity Gap
Drug discovery has scaled - drug development has not
As discovery becomes increasingly industrialized - driven by China, AI, and platform biology - the constraint is no longer access to assets, but the ability to make the right development decisions
This has created a widening gap between what can be discovered and what can be successfully developed, leaving a significant opportunity for more capital-efficient models
Bridging that gap requires a different approach: a development platform that is built to be strategic, repeatable and focused on execution - this is what Weatherden brings to the table
Team
Optimal development does not require a permanent full-time team. Instead, we work smarter, bringing in the right expertise at the right time
Efficiency
We facilitate the efficient deployment of capital for investors by leveraging expertise of an existing, integrated team, with access to proprietary tools
Knowledge
By applying the execution capabilities of our team in a hybrid manner, we can leverage the vast depth of knowledge gained through our Innovation Hub to supercharge development across spinouts
01
Unique insights unlock asset value
Working on >400 programs for partners has generated deep domain insights, illuminating where the next big opportunities may lie. This vantage point means we can identify under-optimized assets with high potential.
02
Asset first venture creation
Assets are selected in collaboration with investment partners. Rooted in rigorous scientific and clinical diligence. We only pursue high-conviction opportunities as we put our team on the line to successfully execute the program.
03
Lean and mean
True to our value of efficiency, the spinco team is built from Weatherden’s core Innovation Team to avoid a fixed cost burden. Programs are successful due to the expertise involved. Our teams tap into central leadership, tools and functional expertise as needed.
04
De-risked delivery
Building teams and executing successfully is a key risk for new ventures. This is entirely circumvented by plugging in a team that knows each other well, working successfully together all the time. This brings enhanced focus on the central goal, and increased operational efficiency.
05
Executing at speed to value inflection
With a fully embedded team from day one the team is laser-focused on delivery of key proof points. This enables value inflection to be achieved more quickly, catalysing further financing, M&A or licensing. Always matching capital to risk.
Unique Model
For Success
In a more capital conscious era innovation is required
Leveraging our expertise in design and execution we identify the appropriate source of funding to create and set up new companies where a focused, hybrid team designs and delivers the program managing risk through to value inflection
Hybrid.
Efficient.
Disrupting.
Spinco 1 - Elevara Medicines
Protocol written & finalized with regulatory submission in <2 months
100% of Series A target raised in <4 months
First patient dosed in <5 months from Series A close
Asset Origin
Teijin Pharma completed a US Ph1b with a differentiated oral CDK4/6 inhibitor, ELV001, in Rheumatoid Arthritis (RA). Teijin approached Weatherden to consider strategic options to optimize value for the asset. We suggested partnering on creating a new company.
Clinical Potential
Standard of Care for RA is methotrexate +
TNF inhibitors, yet responses are variable.
While 50% of patients see a benefit from this combination, many do not reach clinical remission and partial responses continue to impose a negative impact on quality of life.
Add-ons to TNF inhibitors with other immune agents have failed in the past due to increased infection risk. CDK4/6 inhibition offers an orthogonal mechanism that targets the stromal cells vs. immunosuppressants,
lending itself to combination.
Early Ph1b data shows efficacy within one week compared with typical efficacy signals that occur at 8-12 weeks. An agent that enables clinical remission in earlier lines of therapy brings a huge potential benefit to patients globally.
Capital & Terms
Elevara was founded by Weatherden
with corporate operational support and $5M seed funding from Monograph Capital in March 2025.
Weatherden negotiated the license terms.
No upfront, but a 10% equity stake at the Series A valuation plus $30M in commercial-stage milestones and single digit royalties.
A further $70M Series A was raised in
October 2025, co-led by Forbion and Sofinnova
with continued participation from Monograph,
to finance the Ph2 program for ELV001.
Weatherden Delivery
Weatherden had the trial designed and the CRO selection completed by the end of April 2025 ahead of the Series A - proving you can really move fast when you have a capable team plugged in from day one.
The START-SYNERGY Ph2 trial will enrol approximately 180 patients who have inadequate response to methotrexate + TNF inhibitors.
It will be conducted in the US, Europe and S. Africa, with recruitment starting before the end of 2025. First patient was dosed during Q1 2026, <5 months after Series A close.
This enables the delivery of a Ph3 ready asset in TNFi Inadequate Responders RA and unlocks the potential for a Ph2a trial in second-line RA.